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Abstract. Of 53,633 suspected dengue cases reported to a passive dengue surveillance system in Puerto Rico during
2005–2010, 949 individuals were reported on more than one occasion and 21 had laboratory-confirmed dengue on two
separate occasions. Median time between illness episodes was 2.9 years (range: 62 days–5.3 years). Seventeen (81%)
individuals with sequential episodes of dengue were male, and seven (33%) were adults. All 21 individuals experienced
one episode and seven (33%) individuals experienced both episodes during a large epidemic that occurred in 2010. These
observations show that heterotypic dengue virus immunity that protects against illness may have considerable variability
but typically does not last longer than 3 years.
Dengue is the most important vector-borne viral disease
globally,1 and an estimated 96 million cases occurred in 2010.2
Dengue is caused by infection with any of four dengue virus-
types (DENV-1–4) that are transmitted by some Aedes
species mosquitoes.1 Although most DENV infections are
asymptomatic or subclinical,3 ~5% of dengue cases develop
potentially fatal severe dengue, characterized by vascular
leakage and hypovolemic shock.1
Following six outbreaks of dengue-like illness in Galveston,
Texas between 1897 and 1922, Sharp and Hollar estimated that
dengue immunity lasts between 1 and 4 years.4 Later studies by
Sabin involving experimental infection of humans with dif-
ferent DENV-types suggested that cross-protective (i.e., het-
erotypic) immunity protects from illness for 2 months and
attenuates illness for up to 9 months.5 Contemporary studies
of naturally occurring infections in children suggest that het-
erotypic immunity protects against illness for 1–3 years,6–9 and
homotypic immunity is long-lived and specific to the infecting
DENV-type.10
The U.S. Centers for Disease Control and Prevention Den-
gue Branch (CDC-DB) and Puerto Rico Department of
Health (PRDH) have operated the island-wide passive den-
gue surveillance system (PDSS) for several decades,11 which
most recently detected epidemics in 200712 and 201013 (Figure 1)
that were caused primarily by DENV-2 and -3, and DENV-1
and -4, respectively. The objective of this study was to use a
retrospective, descriptive case series to characterize the epide-
miology and DENV immunologic profile of individuals found
to have sequential episodes of dengue as detected by PDSS.
This study was approved by the Institutional Review Boards
at CDC (protocol no. 6383).
Dengue is a reportable health condition in Puerto Rico,
and although the majority of laboratory-positive cases are
identified by PDSS each year,13 the current magnitude of
underreporting of suspected cases is unclear. To report a
suspected dengue case to PDSS, a clinician sends the
patient’s serum specimen along with a Dengue Case Inves-
tigation Form (DCIF) (available at www.cdc.gov/dengue/
resources/dengueCaseReports/DCIF_English.pdf) to CDC-DB.
Following dengue diagnostic testing of specimens, all data are
entered into a secure database, results are reported to the
referring clinicians, and epidemiologic trends are analyzed.
Unique identifiers are used to identify both reported indi-
viduals and their illness episodes. Cases reported with ill-
ness onset dates < 14 days apart and matching names and
dates of birth are consolidated into a single case.
All serum specimens from suspected dengue cases were
tested as previously described.12,13 Briefly, specimens col-
lected within 4 days of illness onset were tested by DENV-
type specific, multiplex reverse transcriptase-polymerase
chain reaction (RT-PCR),14 and specimens collected 6 days
or more after illness onset were tested by anti-DENV
immunoglobulin M (IgM) antibody by capture enzyme-linked
immunosorbent assay (MAC ELISA).15 From 2005 to 2006,
specimens collected 5 days after illness onset were tested only
by RT-PCR. From 2007 to 2010, specimens collected 5 days
after illness onset were tested by both RT-PCR and MAC
ELISA. Laboratory-positive dengue cases were defined either
by detection of DENV nucleic acid by RT-PCR or anti-
DENV IgM antibody by MAC ELISA in a serum specimen.
Neutralizing antibody profiles were determined by micro-
neutralization (MNT) assay16 for all available serum speci-
mens. Due to the possibility of original antigenic sin,17 if an
individual’s illness was defined solely by the presence of anti-
DENV IgM antibody, the infecting DENV-type was defined
solely by a monotypic immune response in which a MNT
titer was present against a single DENV-type.
To identify individuals defined as a laboratory-positive den-
gue case on multiple occasions, the PDSS database was que-
ried for cases with identical dates of birth and first and last
names. Fourteen individuals with a second illness that was
positive solely by MAC ELISA £ 90 days after a previous
laboratory-confirmed episode of dengue were excluded from
further analysis because anti-DENV IgM antibody can in
some cases be detected up to 90 days after illness onset.18
Also excluded from further analysis were two individuals with
DENV-1 and -4 detected in a single specimen in 2010, and
one individual with DENV-2 detected by RT-PCR during
independent illness episodes 16 months apart because virus
could not be isolated from the specimen collected during
the first illness.
Of 53,633 suspected dengue cases reported to PDSS between
January 1, 2005 and December 31, 2010, 949 individuals were
reported on more than one occasion (902 twice, 33 three times,
12 four times, and 2 five times). Of 20,867 laboratory-positive
cases, 21 (0.1%) were individuals that had dengue on at least
two occasions (Table 1). Four (19%) of these individuals (case
ID no. 3, 4, 5, and 10) had serologic evidence of infection with a
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DENV before the first documented episode, suggesting that
they were experiencing tertiary or quaternary DENV infection
on their second documented episode of dengue.
Seventeen (81%) individuals with sequential episodes of
dengue were male (relative risk ratio [RR] = 3.5, 95% confi-
dence interval [95% CI]: 1.2–10.3). Median age during the
first episode was 15 years (range: 0.5–73). Seven (33%) indi-
viduals were adults, which was not significantly different
from all laboratory-positive dengue cases (54%; RR = 0.4,
95% CI: 0.2–1.1). Median time between symptom onset dates
was 2.9 years (range: 62 days–5.3 years). Eight (38%) of the
21 identified individuals experienced the first episode in 2007,
all (100%) experienced the second episode during the 2010
epidemic, and seven (33%) experienced both episodes during
the 2010 epidemic (Figure 1).
Eight (38%) individuals were defined as laboratory-positive
dengue cases by RT-PCR during both episodes, nine (43%) by
MAC ELISA during the first episode and RT-PCR during the
second, three (14%) by RT-PCR during the first episode and
MAC-ELISA during the second, and one (5%) by MAC-
ELISA during both episodes. Both infecting DENV-types
were identified by RT-PCR or inferred by neutralizing anti-
body patterns for 10 individuals, of which five (50%) were
DENV-3 followed by DENV-4, three (30%) were DENV-1
followed by DENV-4, and one (10%) each was DENV-3
followed by DENV-1 and DENV-2 followed by DENV-1.
The duration of heterotypic DENV immunity that protects
against illness has recently been estimated to have an average
duration of 1 to 3 years based on 8 years of data collected
from a prospective pediatric cohort in Nicaragua,9 modeling
of 38 years of dengue surveillance data from Thailand,6 and a
study that used data from two prospective pediatric cohorts
from Thailand involving 2,169 person-years of observation.8
Interestingly, increased time between infections was associ-
ated with increased disease severity in both the Thailand and
Nicaragua cohorts.8,9 In addition, 11 years of surveillance data
from Thailand identified 191 individuals with repeat hospital
admission for laboratory-confirmed dengue, for which the
median interval between dengue episodes was 3.5 years and
ranged from 4 months to 9 years.7 Finally, a study from Puerto
Rico based on at least 13 years of PDSS data showed that of
nine individuals experiencing sequential episodes of dengue,
the median time between episodes was 4 years and ranged
from < 2 to 13 years.19 The present study observed a median
interval of nearly 3 years in 21 individuals with sequential
episodes of dengue, and most episodes occurred during an
epidemic in 2010 that followed a shift in the dominate
DENV-types.12,13,20 These six studies were all differentially
affected by the occurrence of epidemics and consequent dif-
ferences in force of infection; circulating DENV-types and
the order in which infections occurred, which may affect
disease severity21; and an inability to accurately determine
when individuals became susceptible to reinfection. Nonethe-
less, they are all in general agreement that on average hetero-
typic DENV immunity does not protect against illness for
more than 3 years.
Because males consistently represent half of all DENV
infections in Puerto Rico,12,13 an unexpected finding of this
study was that males were more than three times more likely
than females to experience sequential episodes of dengue. Sim-
ilarly, a previous study from Puerto Rico reported that males
represent two-thirds of identified individuals with sequential
episodes of dengue.19 Moreover, although both symptomatic
and inapparent infections were equally distributed by gender
in a Nicaraguan pediatric cohort, repeat DENV infections
appeared to be more frequent in males; however although
this difference only approached statistical significance.9 Taken
together, the findings of these three studies provide weak
evidence for a sex-specific difference in the duration of pro-
tective heterotypic DENV immunity. Previous studies of
Figure 1. Time between illness onset dates for individuals experiencing sequential episodes of dengue in Puerto Rico, 2005–2010 (N = 21).
Plotted on the y axis is the number of reported, laboratory-positive dengue cases each week between 2005 and 2010. Each horizontal black line
represents one individual that experienced sequential episodes of dengue. The start point of each line indicates the onset date of the first reported
illness, and the end point indicates the onset date of the second reported illness. Lines are ordered vertically by length.
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other pathogens have reported that males have increased
susceptibility to infection22 and development of disease,23–25
which may be attributable in part to the effect of estro-
gen.24,26 Additional studies with a larger population of indi-
viduals that experienced sequential episodes of dengue are
therefore needed to confirm the finding of sex-specific differ-
ences in the duration of protective heterotypic immunity and
elucidate potential underlying mechanisms.
As PDSS is more likely to capture severe rather than mild
dengue cases and was previously estimated to have a 10- to
27-fold rate of underreporting,27,28 these surveillance biases
likely led to underestimation of the number of individuals that
experienced sequential episodes of dengue and potential mis-
representation of the median and minimal period of time
between episodes. In addition, the rate of sequential episodes
of dengue observed herein was 0.1% of all reported clinically
apparent dengue cases, which is noticeably less than the 1.2%7
to 2%9 observed in prior studies that used data gathered
through hospital-based surveillance and a prospective cohort
study, respectively. Similarly, the rate of tertiary or quater-
nary DENV infection identified in this study was 0.02% of
all identified dengue cases, compared with a previous obser-
vation of 0.08%.7
A prominent strength of this study was use of surveillance
data from both pediatric and adult health care settings to
identify adults as accounting for one-third of all individuals
with sequential episodes of dengue. Because most, but not
all,5,19 previous studies of heterotypic DENV immunity used
data gathered through surveillance and cohort studies con-
ducted in children, future studies should include adults to
identify potential age-specific differences in the duration of
protective heterotypic immunity. A limitation of this study
was that dengue surveillance in Puerto Rico by definition does
not collect data on asymptomatic DENV infections. Conse-
quently, although we were able to estimate the rate of sequen-
tial dengue episodes over the time frame of this study, we
were unable to estimate the rate of sequential DENV infec-
tions. Similarly, inconsistent reporting of clinical data to
PDSS and unavailability of patients’ medical records pre-
cluded analysis of the association of time between infections
and disease severity.
In conclusion, we identified 21 individuals that had sequen-
tial episodes of dengue in Puerto Rico between 2005 and 2010.
The minimal period of time between episodes was 62 days,
indicating that heterotypic immunity that is protective against
illness can in some cases be quite short-lived, but was most
often < 3 years. This study shows that potential age and sex-
specific differences in protective heterotypic immunity should
be further investigated, specifically in relation to the dosing
regimen of a multivalent dengue vaccine.
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